KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $2.7 billion.

  • Gsk's Net Income towards Common Stockholders rose 370357.56% to $2.7 billion in Q3 2025 from the same period last year, while for Dec 2025 it was $6.7 billion, marking a year-over-year increase of 1981.84%. This contributed to the annual value of $3.3 billion for FY2024, which is 4630.02% down from last year.
  • Per Gsk's latest filing, its Net Income towards Common Stockholders stood at $2.7 billion for Q3 2025, which was up 370357.56% from $1.9 billion recorded in Q2 2025.
  • Gsk's 5-year Net Income towards Common Stockholders high stood at $12.8 billion for Q3 2022, and its period low was -$75.4 million during Q3 2024.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $1.9 billion (2025), whereas its average is $2.5 billion.
  • Per our database at Business Quant, Gsk's Net Income towards Common Stockholders crashed by 10406.38% in 2024 and then skyrocketed by 370357.56% in 2025.
  • Gsk's Net Income towards Common Stockholders (Quarter) stood at $1.0 billion in 2021, then soared by 206.69% to $3.1 billion in 2022, then increased by 24.82% to $3.9 billion in 2023, then decreased by 26.31% to $2.8 billion in 2024, then decreased by 4.65% to $2.7 billion in 2025.
  • Its Net Income towards Common Stockholders stands at $2.7 billion for Q3 2025, versus $1.9 billion for Q2 2025 and $2.0 billion for Q1 2025.